Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature

Volume: 56, Issue: 11, Pages: 1355 - 1362
Published: Aug 19, 2021
Abstract
Introduction Autoimmune pancreatitis (AIP) is a special form of pancreatitis that responds well to glucocorticoid (GC) treatment. Relapses of AIP are common. The anti-CD20 antibody rituximab (RTX) has shown promising results in GC refractory cases, but long-term data are scarce. The study aims to determine the clinical and imaging response to RTX and summarize the existing data on RTX therapy in patients with AIP type 1 in the...
Paper Details
Title
Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature
Published Date
Aug 19, 2021
Volume
56
Issue
11
Pages
1355 - 1362
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.